Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Schwangerschaftsfernüberwachung zur Verbesserung des Zugangs (REACTIVE)

19. Oktober 2026 aktualisiert von: Samuel Parry, MD, University of Pennsylvania

Schwangerschaftsfernüberwachung zur Verbesserung des Zugangs: Die REACTIVE-Studie

The goal of this clinical trial is to determine the effectiveness of remote nonstress test (NST) compared to in-clinic NSTs in improving fetal testing completion rates. Participants will be randomized to either in-clinic NSTs or use of an FDA-approved remote monitoring belt for their pregnancy monitoring.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

400

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • University of Pennsylvania

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Singleton pregnancy
  • Gestational age between 30 weeks 0 days and 35 weeks 6 days
  • Pregnant patients who have clinical indication for fetal surveillance with NSTs (based on UPHS Health System clinical guidelines for antenatal monitoring)
  • Able to provide written consent
  • English speaking

Exclusion Criteria:

  • Multiple gestations
  • Maternal pre-gravid BMI greater than 45kg/m2
  • Presence of an implanted pacemaker or defibrillator
  • Active abdominal skin infection
  • A known amniotic fluid index (AFI) less than 5cm or greater than 25cm on the most recent ultrasound (if available) prior to randomization
  • Delivery is planned within 2 weeks of potential randomization

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Diagnose
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Remote-NST

INVU monitoring belt used for remote NSTs

Aktiver Komparator: NST in der Klinik – Behandlungsstandard

In-clinic NSTs - standard of care

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Fetal Testing Completion Rate
Zeitfenster: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Percentage of recommended antenatal testing sessions successfully completed, defined as a clinically interpreted test performed. Calculated for each participant as: number of NST visits completed divided by number of NST visits expected × 100.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Fetal Testing Completion Rate in Black Versus Non-Black Subjects
Zeitfenster: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Comparison between Black and non-Black subjects' percentage of recommended antenatal testing sessions that were successfully completed as defined as a clinically interpreted test was performed. Calculated as the number of NST visits completed divided by the number of NST visits expected per participant × 100.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Fetal Monitoring Outcomes: Number of Visits to the Antenatal Testing Unit
Zeitfenster: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Count of visits to the office for in-person monitoring

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Fetal Monitoring Outcomes: Percentage of Non-Stress Test Sessions Requiring Provider-Recommended Prolonged Monitoring
Zeitfenster: From randomization until delivery.

For each participant, the percentage of all NST sessions requiring prolonged monitoring (>40 minutes) was calculated. The median participant-level percentage is reported.

From randomization until delivery.
Fetal Monitoring Outcomes: Average Duration of Non-Stress Test Monitoring Sessions
Zeitfenster: From randomization until delivery.

Mean duration of NST monitoring sessions across all NSTs completed by each participant from randomization to delivery. Participant-level means were calculated and summarized by study arm.

From randomization until delivery.
Fetal Monitoring Outcomes: Non-reactive NST Rate
Zeitfenster: From randomization until delivery

Percentage of NSTs that were non-reactive among all NSTs completed for each participant.

From randomization until delivery
Fetal Monitoring Outcomes: Percentage of NSTs Resulting in Biophysical Profile Evaluation
Zeitfenster: From randomization until delivery.

Percentage of completed NSTs followed by biophysical profile assessment.

From randomization until delivery.
Fetal Monitoring Outcomes: Number of Participants With ≥1 Obstetrical Triage Visit
Zeitfenster: From randomization to delivery

Number of Participants With ≥1 Obstetrical Triage Visit

From randomization to delivery
Fetal Monitoring Outcomes: Number of Participants Who Had Any Triage Visit Directly Related to a Fetal Monitoring Visit
Zeitfenster: From randomization to delivery

Number of participants who underwent at least one obstetrical triage evaluation directly related to a fetal monitoring visit, during the study period from randomization until delivery.

From randomization to delivery
Fetal Monitoring Outcomes: Number of Participants Recommended for Delivery Based on Findings on Fetal Monitoring Result
Zeitfenster: From randomization to delivery

Count of the number of subjects in each arm who receive a recommendation for delivery based on the findings of the fetal monitoring results.

From randomization to delivery
Fetal Monitoring Outcomes: Percentage of NSTs Not Completed Within the Prescribed Window
Zeitfenster: from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Percentage of NSTs which occur outside of prescribed window, for example, if a weekly testing regimen is prescribed, an appointment 8 or more days following the last one would count as 1 missed calendar window.

from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.
Obstetrics Outcomes: Gestational Age at Delivery
Zeitfenster: time of delivery

gestational age at time of delivery

time of delivery
Obstetrics Outcomes: Number of Participants With Preterm Delivery
Zeitfenster: time of delivery

preterm delivery is defined as less than 37 weeks gestational age

time of delivery
Obstetrics Outcomes: Mode of Delivery
Zeitfenster: time of delivery

categorized as vaginal or cesarean

time of delivery
Obstetrics Outcomes: Number of Participants With an Indication for Labor Induction
Zeitfenster: time of labor induction

in subjects who have labor induction, indication for inducing labor

time of labor induction
Obstetrics Outcomes: Number of Participants With an Indication for Cesarean Section
Zeitfenster: time of delivery

in subjects who have a cesarean section delivery, indication for cesarean section

time of delivery
Obstetrics Outcomes: Number of Participants With Composite Neonatal Morbidity
Zeitfenster: from delivery to 6 weeks post-delivery

Number of participants whose neonate experienced at least one component of the composite neonatal morbidity outcome, defined as severe respiratory distress, neonatal resuscitation outside the delivery room, or neonatal death.

from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Neonatal Cord Blood pH
Zeitfenster: time of delivery
time of delivery
Obstetrics Outcomes: Apgar Scores
Zeitfenster: one and five minutes after delivery

Apgar score at 1 and 5 minutes after delivery. Scores range from 0 to 10, with higher scores indicating better neonatal condition

one and five minutes after delivery
Obstetrics Outcomes: Number of Participants With an Admission to the Neonatal Intensive Care Unit
Zeitfenster: from delivery to 6 weeks post-delivery
from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Number of Participants Who Had an Admission to the Neonatal Intensive Care Unit for Greater Than 48 Hours
Zeitfenster: from delivery to 6 weeks post-delivery
from delivery to 6 weeks post-delivery
Obstetrics Outcomes: Maternal Length of Hospital Stay
Zeitfenster: Delivery hospitalization

Length of maternal hospitalization associated with the delivery admission, measured from hospital admission for delivery through maternal discharge.

Delivery hospitalization
Obstetrics Outcomes: Neonatal Length of Hospital Stay
Zeitfenster: Birth hospitalization

Length of neonatal hospitalization from birth through hospital discharge.

Birth hospitalization
Cost-effectiveness Outcomes: Productivity Loss Due to Antenatal Testing and Monitoring
Zeitfenster: From randomization until delivery (approximately 10 weeks on average)

Productivity loss was assessed by summing the number of days of work missed reported by participants across the two study productivity assessments. The reported value represents the total number of work days missed during the study period for each participant.

From randomization until delivery (approximately 10 weeks on average)
Cost-effectiveness Outcomes: Total Societal Perspective Cost
Zeitfenster: Randomization through delivery

Total societal perspective cost per participant, calculated as the sum of direct healthcare costs, informal healthcare costs, and productivity costs incurred from randomization through delivery. Costs are reported in U.S. dollars (USD). The societal perspective includes costs related to antenatal testing, delivery hospitalization, neonatal care, triage visits, antepartum admissions, productivity losses, caregiving, and transportation.

Randomization through delivery
Implementation Outcomes: Theory-informed Acceptability Questionnaire
Zeitfenster: at time of delivery

Participant acceptability of the assigned fetal monitoring strategy was assessed using an 8-item Theory-Informed Acceptability Questionnaire (TFA). Total scores range from 8 to 40, with higher scores indicating greater acceptability of the monitoring approach.

at time of delivery

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

25. Mai 2023

Primärer Abschluss (Tatsächlich)

26. September 2025

Studienabschluss (Tatsächlich)

26. September 2025

Studienanmeldedaten

Zuerst eingereicht

27. April 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. April 2023

Zuerst gepostet (Tatsächlich)

8. Mai 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 852291

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .